Nestec S.a.

Institut Curie

Societe Des Produits Nestle S.a.

Novartis Pharma Gmbh

Kevin Burke Miller

Norman Alan Greenberg

Eduardo Schiffrin

Michael John Tisdale

Dominique Brassart

Lionel Jean Rene Bovetto

Sebastian Amigorena

Kala Marie Kaspar

Zamzam (Fariba) Roughead

Julie Ann Swanson

Anne L Falk

Olivier Jacques Lantz

Candis Diane Kvamme

Zamzam Kabiry Roughead

Trent Stellingwerff

Helen Laura Eley

Satya Jonnalagadda

Lionel Jean Bovetto

Lionel Jean René Bovetto

Helen Eley

Michael Tisdale

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor

The invention provides compounds for use in a method of treating oral pharyngeal dysphagia in an individual and related products. One embodiment of the invention comprises administering to an individual an effective amount of a vanilloid receptor 1 (VR-1) agonist or high-affinity partial agonist to promote a swallow reflex.

Treatment of oral pharyngeal dysphagia

Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides nutritional compositions having whey protein micelles and leucine. The nutritional compositions provide a sufficient amount of leucine to improve protein synthesis in humans, while also maintaining a low-viscosity fluid matrix and acceptable organoleptic properties.

Compositions for masking the flavor of nutrients and methods for making same

Disclosed is a method and composition for nutritional compositions containing glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome/Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.

Methods of use and nutritional compositions of Touchi Extract

The invention provides methods for treating muscle loss in an individual. In one embodiment, the invention includes administering to an individual an effective amount of a branched chain amino acid (BCAA), a BCAA precursor, a BCAA metabolite, a BCAA-rich protein, a protein manipulated to enrich the BCAA content or any combination thereof. The invention further provides nutritional products for such administration, including orally-administrable nutritional products.

Methods for the treatment of muscle loss

Growing community of inventors

Minneapolis, MN, United States of America

Kevin Burke Miller